Lupin rolls out Nasal spray for rhinorrhea relief in US
Mumbai: Global pharma major Lupin Limited has launched Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States.
Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals, Inc.
Ipratropium Bromide Nasal Solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older.
Ipratropium Bromide Nasal Solution (Nasal Spray) 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older.
In January 2025, the Medical Dialogues team reported that Lupin had received USFDA approval for its Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution (0.06%).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.